The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine/naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid while on abstinent therapy. In most markets, regardless of which type of opioid addiction treatment received, relapse rates among opioid addicts remain high. Thus, commercial opportunity exists for new opioid addiction treatments, particularly those that can more effectively reduce the craving and opioid use and do not have an abuse potential.
- How is opioid addiction currently treated in the major pharmaceutical markets? What are interviewed experts’ opinions of current opioid addiction therapies?
- What are the greatest unmet needs in terms of treating opioid addiction and to what extent will these needs be fulfilled in the next ten years?
- What do interviewed experts think about late-phase emerging therapies such as long-acting depot buprenorphine products from Camurus/Braeburn Pharmaceuticals (CAM-2038) and Indivior (RBP-6000)?
- What is the commercial potential of late-phase pipeline products in the opioid addiction market should they launch?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Opioid Addiction - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Angela Sparrow, Ph.D.
Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.
Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.